Reikvam and colleagues [101] demonstrated that PI3K and mTOR inhibitors exerted direct and indirect antileukemic activity through the inhibition of angioregulatory mediators released by both AML and stromal cells. This evidence concerns the gene MTOR and acute myeloid leukemia.